Literature DB >> 11734767

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons.

X Carbonell-Estrany1, J Quero.   

Abstract

OBJECTIVE: To collect data on hospitalization rates for respiratory syncytial virus (RSV) illness during the season of 1999 to 2000 in nonprophylaxed premature infants < or = 32 weeks gestational age (GA) in Spain and compare this with previously published data collected in the season of 1998 to 1999.
METHODS: Children born at < or = 32 weeks GA between April 1, 1999, and April 31, 2000, and discharged from the hospital before April 31, 2000, were included. Neonatal and demographic data were obtained at the initial visit. Study subjects were followed at monthly intervals throughout the respiratory season. RSV status and morbidity data were collected on patients rehospitalized for respiratory illness.
RESULTS: The 999 evaluable patients in the 2000 season were comparable to the 1999 sample, except for higher rates of family allergy history and number of multiple deliveries and a lower rate of neonatal morbidity. The hospitalization rate for RSV illness was 13.4% in the 1999 season and 13.1% in the 2000 season; 10 (8%) were RSV reinfections in the 2000 season. Significant independent prognostic variables for high risk of RSV hospital admission included: lower gestational age; chronologic age < 3 months at onset of the RSV season; living with school age siblings; and exposure to tobacco smoke.
CONCLUSIONS: Hospitalization rates for RSV disease in nonprophylaxed preterm infants < or = 32 weeks GA were high in Spain and comparable during two consecutive RSV seasons (13%). Readmission for a second RSV infection was also common.

Entities:  

Mesh:

Year:  2001        PMID: 11734767     DOI: 10.1097/00006454-200109000-00010

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  35 in total

1.  Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Authors:  T Heikkinen; H Valkonen; L Lehtonen; R Vainionpää; O Ruuskanen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-01       Impact factor: 5.747

2.  A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-01       Impact factor: 3.267

3.  Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Authors:  Caroline Fenton; Lesley J Scott; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

4.  Combined effects of chronic nicotine and acute virus exposure on neurotrophin expression in rat lung.

Authors:  Fernando Urrego; Mario Scuri; Alexander Auais; Lida Mohtasham; Giovanni Piedimonte
Journal:  Pediatr Pulmonol       Date:  2009-11

5.  Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein.

Authors:  L de Waal; S Yüksel; A H Brandenburg; J P M Langedijk; K Sintnicolaas; G M G M Verjans; A D M E Osterhaus; R L de Swart
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Lower respiratory tract illness and RSV prophylaxis in very premature infants.

Authors:  T Lacaze-Masmonteil; P Truffert; D Pinquier; P Daoud; G Goldfarb; E Vicaut; B Fauroux
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

Review 7.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

Review 8.  Prematurity and the burden of influenza and respiratory syncytial virus disease.

Authors:  Bernhard Resch; Stefan Kurath-Koller; Monika Eibisberger; Werner Zenz
Journal:  World J Pediatr       Date:  2015-11-19       Impact factor: 2.764

Review 9.  Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.

Authors:  Joseph R DiFranza; Anthony Masaquel; Amy M Barrett; Ann D Colosia; Parthiv J Mahadevia
Journal:  BMC Pediatr       Date:  2012-06-21       Impact factor: 2.125

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.